Jan Skvarka - Jun 13, 2025 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
Director
Signature
/s/ Markus Warmuth, Attorney-in-Fact
Stock symbol
GLUE
Transactions as of
Jun 13, 2025
Transactions value $
$0
Form type
4
Date filed
6/16/2025, 04:05 PM
Previous filing
Feb 4, 2025
Next filing
Jun 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Skvarka Jan Director MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON /s/ Markus Warmuth, Attorney-in-Fact 2025-06-16 0001838042

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLUE Stock Option (Right to Buy) Award $0 +30.7K $0.00 30.7K Jun 13, 2025 Common Stock 30.7K $4.91 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.